A Systematic Review of the Impact of Surgeon and Hospital Caseload Volume on Oncological and Nononcological Outcomes After Radical Prostatectomy for Nonmetastatic Prostate Cancer.


Journal

European urology
ISSN: 1873-7560
Titre abrégé: Eur Urol
Pays: Switzerland
ID NLM: 7512719

Informations de publication

Date de publication:
11 2021
Historique:
received: 26 12 2020
accepted: 19 04 2021
pubmed: 9 5 2021
medline: 29 3 2022
entrez: 8 5 2021
Statut: ppublish

Résumé

The impact of surgeon and hospital volume on outcomes after radical prostatectomy (RP) for localised prostate cancer (PCa) remains unknown. To perform a systematic review on the association between surgeon or hospital volume and oncological and nononcological outcomes following RP for PCa. Medline, Medline In-Process, Embase, and the Cochrane Central Register of Controlled Trials were searched. All comparative studies for nonmetastatic PCa patients treated with RP published between January 1990 and May 2020 were included. For inclusion, studies had to compare hospital or surgeon volume, defined as caseload per unit time. Main outcomes included oncological (including prostate-specific antigen persistence, positive surgical margin [PSM], biochemical recurrence, local and distant recurrence, and cancer-specific and overall survival) and nononcological (perioperative complications including need for blood transfusion, conversion to open procedure and within 90-d death, and continence and erectile function) outcomes. Risk of bias (RoB) and confounding assessments were undertaken. Both a narrative and a quantitative synthesis were planned if the data allowed. Sixty retrospective comparative studies were included. Generally, increasing surgeon and hospital volumes were associated with lower rates of mortality, PSM, adjuvant or salvage therapies, and perioperative complications. Combining group size cut-offs as used in the included studies, the median threshold for hospital volume at which outcomes start to diverge is 86 (interquartile range [IQR] 35-100) cases per year. In addition, above this threshold, the higher the caseload, the better the outcomes, especially for PSM. RoB and confounding were high for most domains. Higher surgeon and hospital volumes for RP are associated with lower rates of PSMs, adjuvant or salvage therapies, and perioperative complications. This association becomes apparent from a caseload of >86 (IQR 35-100) per year and may further improve hereafter. Both high- and low-volume centres should measure their outcomes, make them publicly available, and improve their quality of care if needed. We reviewed the literature to determine whether the number of prostate cancer operations (radical prostatectomy) performed in a hospital affects the outcomes of surgery. We found that, overall, hospitals with a higher number of operations per year have better outcomes in terms of cancer recurrence and complications during or after hospitalisation. However, it must be noted that surgeons working in hospitals with lower annual operations can still achieve similar or even better outcomes. Therefore, making hospital's outcome data publicly available should be promoted internationally, so that patients can make an informed decision where they want to be treated.

Identifiants

pubmed: 33962808
pii: S0302-2838(21)00298-0
doi: 10.1016/j.eururo.2021.04.028
pii:
doi:

Types de publication

Journal Article Review Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

531-545

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021. Published by Elsevier B.V.

Auteurs

Thomas Van den Broeck (T)

Department of Urology, University Hospitals Leuven, Leuven, Belgium. Electronic address: thomas.vandenbroeck@uzleuven.be.

Daniela Oprea-Lager (D)

Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centres, VU University, Amsterdam, The Netherlands.

Lisa Moris (L)

Department of Urology, University Hospitals Leuven, Leuven, Belgium.

Mithun Kailavasan (M)

Leicester City Hospital, Leicester, UK.

Erik Briers (E)

Hasselt, Belgium.

Philip Cornford (P)

Department of Urology, Liverpool University Hospitals, Liverpool, UK.

Maria De Santis (M)

Department of Urology, Charité University Hospital, Berlin, Germany; Department of Urology, Medical University of Vienna, Vienna, Austria.

Giorgio Gandaglia (G)

Unit of Urology, Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.

Silke Gillessen Sommer (S)

Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Università della Svizzera Italiana, Lugano, Switzerland.

Jeremy P Grummet (JP)

Department of Surgery, Central Clinical School, Monash University, Australia.

Nikos Grivas (N)

Department of Urology, Hatzikosta General Hospital, Ioannina, Greece.

Thomas B L Lam (TBL)

Department of Urology, Aberdeen Royal Infirmary, Aberdeen, UK.

Michael Lardas (M)

Department of Urology, Metropolitan General Hospital, Athens, Greece.

Matthew Liew (M)

Department of Urology, Wrightington, Wigan and Leigh Teaching Hospitals NHS Foundation Trust, Wigan, UK.

Malcolm Mason (M)

Division of Cancer & Genetics, School of Medicine Cardiff University, Velindre Cancer Centre, Cardiff, UK.

Shane O'Hanlon (S)

Medicine for Older People, Saint Vincent's University Hospital, Dublin, Ireland.

Jakub Pecanka (J)

Pecanka Consulting Services, Prague, Czech Republic.

Guillaume Ploussard (G)

La Croix du Sud Hospital, Quint Fonsegrives, France.

Olivier Rouviere (O)

Hospices Civils de Lyon, Department of Urinary and Vascular Imaging, Hôspital Edouard Herriot, Lyon, France.

Ivo G Schoots (IG)

Department of Radiology & Nuclear Medicine, Erasmus MC University Medical Centre, Rotterdam, The Netherlands; Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands.

Derya Tilki (D)

Martini-Klinik Prostate Cancer Centre, Hamburg, Germany; Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.

Roderick C N van den Bergh (RCN)

Department of Urology, Antonius Hospital, Utrecht, The Netherlands.

Henk van der Poel (H)

Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands.

Thomas Wiegel (T)

Department of Radiation Oncology, University Hospital Ulm, Ulm, Germany.

Peter-Paul Willemse (PP)

Department of Oncological Urology, University Medical Centre, Utrecht Cancer Centre, Utrecht, The Netherlands.

Cathy Y Yuan (CY)

Department of Medicine, Health Science Centre, McMaster University, Hamilton, Ontario, Canada.

Nicolas Mottet (N)

Department of Urology, University Hospital, St. Etienne, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH